Gainers

• Relmada Therapeutics (NASDAQ:RLMD) stock rose 48.3% to $6.6 during Monday's pre-market session. The market value of their outstanding shares is at $326.3 million.
• Hims & Hers Health (NYSE:HIMS) shares rose 44.09% to $22.68. The market value of their outstanding shares is at $3.5 billion.
• Xenon Pharmaceuticals (NASDAQ:XENE) stock moved upwards by 42.48% to $59.76. The market value of their outstanding shares is at $3.2 billion.
• uniQure (NASDAQ:QURE) shares increased by 36.58% to $19.49. The market value of their outstanding shares is at $888.9 million.
• Dianthus Therapeutics (NASDAQ:DNTH) shares moved upwards by 24.23% to $81.0. The company's market cap stands at $2.8 billion. As per the press release, Q4 earnings came out today.
• Atara Biotherapeutics (NASDAQ:ATRA) shares moved upwards by 22.24% to $6.32. The company's market cap stands at $37.2 million.

Losers

• Olema Pharmaceuticals (NASDAQ:OLMA) shares decreased by 42.6% to $12.36 during Monday's pre-market session. The company's market cap stands at $1.7 billion.
• Zymeworks (NASDAQ:ZYME) stock declined by 33.1% to $16.11. The company's market cap stands at $1.8 billion.
• ProQR Therapeutics (NASDAQ:PRQR) stock declined by 15.74% to $1.5. The company's market cap stands at $188.5 million.
• Cuprina Holdings (Cayman) (NASDAQ:CUPR) stock fell 15.08% to $0.33. The market value of their outstanding shares is at $2.8 million.
• Aura Biosciences (NASDAQ:AURA) shares declined by 11.43% to $4.96. The company's market cap stands at $355.6 million.
• CEL-SCI (AMEX:CVM) stock fell 10.92% to $3.51. The market value of their outstanding shares is at $27.1 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.